Our Strategy

At Horizon, our passion for bringing breakthrough medicines to more patients in need drives our partnering strategy. As one of the fastest growing biopharmaceutical companies, our strong partnerships have enabled us to become a leader in rare diseases. With our strategic focus on building a balanced development pipeline and openness to transformative merger and acquisition opportunities, we’re actively looking for partnerships where we can achieve goals together.

Midpoint of 2020 sales guidance; Enterprise value as of 4/15/2020

Partner of Choice

The unique attributes we bring to the table make us a partner of choice.

Our seasoned commercial and medical leadership has extensive pharmaceutical brand experience. With approximately 500 field representatives covering nearly 55,000 unique physician specialists and 40 field-based medical directors, we have significant resources to support successful product launch and commercialization.

  • Expertise in market shaping and strategic brand positioning
  • Optimized go-to-market model for complex, multi-specialty therapies
  • High-touch, patient-centric model
  • Exceptional sales execution, including ability to recruit, retain and motivate talent

Through a proven track record and more than 200 combined years of development experience on more than 100 medicines spanning many therapeutic areas, we are able to agilely execute and deliver results:

  • Life cycle management expertise to drive patient benefit and competitive position
  • Innovative and agile development approach, especially when pathway may be unchartered

Our robust supply-chain management of more than 40 contract manufacturing organizations ensures global product quality, chemistry manufacturing and controls, supply and distribution through our virtual model.

  • Breadth of experience from controlled release oral dosage to complex biologics

Our Areas of Interest

Horizon seeks opportunities aimed at bolstering our clinical-stage pipeline through licensing, acquiring or partnering clinical-stage assets. Our team is currently evaluating opportunities with a focus on developing new and novel therapies in our core areas of focus:

Rare Disease

玩弄放荡人妇系列Rheumatology

Nephrology

Ophthalmology

Endocrinology

玩弄放荡人妇系列Within these areas of focus, we are seeking opportunities that present key characteristics:

  • Therapies that address a significant unmet need
  • Diseases with smaller patient populations
  • Medicines that provide an opportunity to add value through shaping the regulatory paradigm and commercial landscape

玩弄放荡人妇系列We are also open to exploring partnerships in other therapeutic areas of significant unmet need.

Our Collaborations

Our ability to successfully bring medicines to market has brought strong returns to our partners. Through early collaborations focused on commercial-stage opportunities, we’ve built a robust infrastructure that can be leveraged in current and future research and development endeavors. Our strong performance has created a solid financial platform that continues to provide resources for future investments in research and development.

Example Collaborations

EMEA collaboration for

PROCYSBI and QUINSAIR

HZN-007(Next-Gen Gout Program)

Gout Research

Collaboration

What Makes a Successful Collaboration?

Our team has completed eight transactions worth more than $3 billion over the last seven years. We are open to working with partners in various ways, to meet the objectives of both parties. Here are just some of the reasons to partner with us:

Significant executive
engagement

Efficient
玩弄放荡人妇系列decision-making process

Collaborative and
flexible partnerships

Strong alliance
management

玩弄放荡人妇系列Win-win partnerships

Committed to the success of
玩弄放荡人妇系列partnered assets

Download Our Full Partnering Overview

Download PDF

Our experienced team is led by Andy Pasternak, executive vice president and chief strategy officer; Joe Whalen, senior vice president, business development and alliance management; and Mike Kelliher, vice president, business development. If you would like to submit partnering inquiries, please contact us at bd@einhammr.com.

秒速赛车【gd1133.com光大彩票】-新闻 秒速赛车【gd1100.com光大彩票】-法治 秒速赛车【gd1144.com光大彩票】-案件 秒速赛车【gd1155.com光大彩票】-检察 秒速赛车【gd1166.com光大彩票】-理论 秒速赛车【gd1177.com光大彩票】-新媒体 秒速赛车【gd9900.com光大彩票】-视频 秒速赛车【gd9911.com光大彩票】-评论 秒速赛车【gd9922.com光大彩票】-文化 秒速赛车【gd9933.com光大彩票】-人物 秒速赛车【gd9944.com光大彩票】-舆情 秒速赛车【gd9955.com光大彩票】-装备 玩弄放荡人妇系列 秒速赛车【gd9977.com光大彩票】-今日推荐 秒速赛车【gd1133.com光大彩票】-图片聚焦 秒速赛车【gd1100.com光大彩票】-以案说法 秒速赛车【gd1144.com光大彩票】-检察视界 秒速赛车【gd1155.com光大彩票】-城东区 秒速赛车【gd1166.com光大彩票】-城中区 秒速赛车【gd1177.com光大彩票】-城西区 秒速赛车【gd9900.com光大彩票】-城北区 秒速赛车【gd9911.com光大彩票】-大通县 秒速赛车【gd9922.com光大彩票】-湟中县 秒速赛车【gd9933.com光大彩票】-湟源县 秒速赛车【gd9944.com光大彩票】-经济技术开发区 秒速赛车【gd9955.com光大彩票】-城南新区 秒速赛车【gd9977.com光大彩票】-高新技术开发区 秒速赛车【gd1133.com光大彩票】-海湖新区 秒速赛车【gd1100.com光大彩票】-玩弄放荡人妇系列 秒速赛车【gd1144.com光大彩票】-滚动 秒速赛车【gd1155.com光大彩票】-国内 秒速赛车【gd1166.com光大彩票】-国际 秒速赛车【gd1177.com光大彩票】-军事 秒速赛车【gd9900.com光大彩票】-社会 秒速赛车【gd9911.com光大彩票】-财经 秒速赛车【gd9922.com光大彩票】-产经 秒速赛车【gd9933.com光大彩票】-房产 秒速赛车【gd9944.com光大彩票】-金融 秒速赛车【gd9955.com光大彩票】-证券 秒速赛车【gd9977.com光大彩票】-汽车 秒速赛车【gd1133.com光大彩票】-IT 秒速赛车【gd1100.com光大彩票】-能源 秒速赛车【gd1144.com光大彩票】-港澳 秒速赛车【gd1155.com光大彩票】-台湾 秒速赛车【gd1166.com光大彩票】-华人 秒速赛车【gd1177.com光大彩票】-侨网 秒速赛车【gd9900.com光大彩票】-经纬 秒速赛车【gd9911.com光大彩票】-English 秒速赛车【gd9922.com光大彩票】-图片 秒速赛车【gd9933.com光大彩票】-视频 秒速赛车【gd9944.com光大彩票】-直播 北京PK10【gd9955.com光大彩票】-娱乐 PK10开奖【gd9977.com光大彩票】-体育 pk10平台【gd1133.com光大彩票】-文化 Pk10计划【gd1100.com光大彩票】-健康 pk10网址【gd1144.com光大彩票】-生活 pk10开户【gd1155.com光大彩票】-葡萄酒 pk10赛车【gd1166.com光大彩票】-微视界 PK10投注平台【gd1177.com光大彩票】-演出 PK10注册【gd9900.com光大彩票】-专题 PK10开户【gd9911.com光大彩票】-理论 北京PK10【gd9922.com光大彩票】-新媒体 PK10开奖【gd9933.com光大彩票】-供稿 pk10平台【gd9944.com光大彩票】-新闻 Pk10计划【gd9955.com光大彩票】-时事 pk10网址【gd9977.com光大彩票】-视频 pk10开户【gd1133.com光大彩票】-评论 pk10赛车【gd1100.com光大彩票】-股票 PK10投注平台【gd1144.com光大彩票】-区块链 PK10注册【gd1155.com光大彩票】-港股 PK10开户【gd1166.com光大彩票】-科创 北京PK10【gd1177.com光大彩票】-基金 PK10开奖【gd9900.com光大彩票】-私募 pk10平台【gd9911.com光大彩票】-理财 Pk10计划【gd9922.com光大彩票】-信托 pk10网址【gd9933.com光大彩票】-P2P pk10开户【gd9944.com光大彩票】-科技 pk10赛车【gd9955.com光大彩票】-债券 PK10投注平台【gd9977.com光大彩票】-互金 PK10注册【gd1133.com光大彩票】-期货 PK10开户【gd1100.com光大彩票】-原油 北京PK10【gd1144.com光大彩票】-大宗 PK10开奖【gd1155.com光大彩票】-期指 pk10平台【gd1166.com光大彩票】-保险 Pk10计划【gd1177.com光大彩票】-银行 pk10网址【gd9900.com光大彩票】-黄金 pk10开户【gd9911.com光大彩票】-外汇 pk10赛车【gd9922.com光大彩票】-行情 PK10投注平台【gd9933.com光大彩票】-数据 PK10注册【gd9944.com光大彩票】-房产 PK10开户【gd9955.com光大彩票】-汽车 北京PK10【gd9977.com光大彩票】-博客 PK10开奖【gd1133.com光大彩票】-农金 pk10平台【gd1100.com光大彩票】-名家 Pk10计划【gd1144.com光大彩票】-消金 pk10网址【gd1155.com光大彩票】-美股 pk10开户【gd1166.com光大彩票】-创投 pk10赛车【gd1177.com光大彩票】-游戏 PK10投注平台【gd9900.com光大彩票】-滚动 PK10注册【gd9911.com光大彩票】-新浪 PK10开户【gd9922.com光大彩票】-正义网